CLINICAL TRIALS PROFILE FOR NIACOR
✉ Email this page to a colleague
All Clinical Trials for NIACOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00176020 ↗ | Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression | Unknown status | Heidelberg University | Phase 1 | 1969-12-31 | The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be: - Treatment A: 500 mg nicotinic acid (Niacor(R)) - Treatment B: Niacor(R) Placebo Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination. |
| NCT00953667 ↗ | The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study | Completed | University of Pennsylvania | N/A | 2007-06-01 | The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers. |
| NCT02003638 ↗ | Assessment Of Vascular Health After Niacin Therapy (AVANT) | Completed | University of Pennsylvania | N/A | 2012-03-01 | This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic statin therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NIACOR
Condition Name
Clinical Trial Locations for NIACOR
Trials by Country
Clinical Trial Progress for NIACOR
Clinical Trial Phase
Clinical Trial Sponsors for NIACOR
Sponsor Name
